Sirona Biochem (Seite 3102)

[dottore]

sehr schwer einzuschätzen. Gleichzeitig gibt es eine Reihe anderer Investmöglichkeiten, die mir mehr bei weniger Aufwand versprechen.

Ich glAUBE NICHT; DASS ICH HIER EINSTEIGEN WERDE:

fINDE GUT; DASS DU selbst distanziert schreibst und nicht blind puschst.
Finde die kritischen Beiträge von DJ etwas zu persönlich angreifend.

Viel Glück hier, besser: Investier wo anders!

[Jon_Schnee]

Antwort auf Beitrag Nr.: 46.110.831 von Jon_Schnee am 25.12.13 08:41:35

Grösste Fanatasie derzeit sicher bei Skin Lightening
http://www.sironabiochem.com/wp-content/uploads/2013/05/SBM-…

2 ähnlihce Wirkstoffe:

TFC-849: Gib's ein LOI ->
Sirona Biochem Signs Letter of Intent with Obagi Medical Products
http://www.sironabiochem.com/sirona-biochem-signs-letter-of-…

Obagi wurde von Valenat übernommen:
Valeant Pharmaceuticals International, Inc. Agrees to Acquire Obagi Medical Products, Inc. for $19.75 Per Share in Cash

Valeant Pharmaceuticals International, Inc. (VRX) -NYSE 
Kurs: 113 USD / Market Cap: 37.74B / Revenue (ttm): 4.69B

VALEANT ist also kein kleines Unternehmen.

-> hier hoffe ich bei Unterschrift auf eine erste Milestone Zahlung.
Wenn das nicht passiert -> neue Verwässerung!!!


and TFC-723: ??? Hoffe auf einen anderen Major

[Jon_Schnee]

Antwort auf Beitrag Nr.: 46.109.615 von dottore am 24.12.13 13:55:41

Ciao Dottore

gerngesehen - Der Thread ist zu einem Tagebuch resp. Info Sammlung verkommen als zu einer Diskussion Plattform. Anscheinend kein Interesse in Deutschland an Sirona. Na Ja, nicht desto trotz ist das kleine Ding in 2013 um 66% gestiegen Und ist jetzt ca. 30Mio CAD schwer.

Es gibt durchaus Intresse an der Plattform http://www.sironabiochem.com/ von Sirona:
siehe Diverse LOI "Letter of Intent" : http://www.sironabiochem.com/sirona-biochem-corporation-ceos…" target="_blank" rel="nofollow ugc noopener">http://www.sironabiochem.com/sirona-biochem-corporation-ceos…


Bis jetzt kam es aber nur zu einem Vertrag durch einen solchen LOI:
Sirona Biochem Announces Signing of Deal for Collaboration with Bloom Burton & Co.
Read more at http://www.stockhouse.com/news/press-releases/2013/12/04/sir…" target="_blank" rel="nofollow ugc noopener">http://www.stockhouse.com/news/press-releases/2013/12/04/sir…

-> Langfristig sicher eine gute Sache.


Jedoch löst es das GROSSE PROBLEM von Sirona derzeit nicht.
Und hier liegt der Hund begraben.

Finanzierung: Company ist recht klamm. Wenn nicht bald ein neuer Vertrag unterschrieben wird heisst das erneut Verwässerung. Evt. auch mit Vertrag.
und es sind schon 200M Aktien drausen.

Potential ist riesig bei Sirona:
http://www.sironabiochem.com/products/pipeline/
Besonders der Kosmetik Bereich -> Skin Lightening / Anti Aging
Langfristig aber der Pharma Bereich.

Mit einem Kurs von 0.15 CAD hängt man ein wenig in der Luft für einen neuen Einstieg finde ich:

Wenn eine Finanzierung kommt ohne gute News dazu oder die Märkte einbrechen geht's vermutlich wieder schnell Richtung 0.12 CAD oder tiefer.
Wenn jedoch all die LOI in Verträge Zeitnah umgewandelt werden kann es durchaus schnell raufgehen.

So das sind meine Überlegungen. Deine?

Schöne Festtage noch

[dottore]

@Jon_Schnee danke für Info und deine Ausdauer

Dass in all den Monaten hier so wenig Resonanz zu finden war, ändert nichts daran, dass der Kurs sich in der gleichen Zeit in etwa verdoppelt hat.
Trotz allem fällt es mir schwer, ein Urteil zu finden. Lohnt sich ein Invest, oder doch nicht? Der Kurs ist ja schon gewaltig gestiegen ....

Und wenn ich das mit der Kapitalerhöhung richtig verstanden habe, dann sind jetzt rund 200 Mio Aktien da, somit eine Marktkapitalisierung von etwa 30 Mio Cad $

Immer noch wenig.

Wenn so viel dran wär, wie du glaubst, wieso kommt kein anderer drauf und warum steht die Aktie nicht bei 1 $?

[Jon_Schnee]

Sirona Biochem Announces Signing of Deal for Collaboration with Bloom Burton & Co.

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Dec. 4, 2013) - Sirona Biochem Corp. (TSX VENTURE:SBM)(OTCQX:SRBCF) and Bloom Burton & Co. ("Bloom Burton") announce the signing of a joint venture to conduct collaborative research to develop and commercialize new therapeutics in the areas of inflammation and infectious disease.

Sirona and Bloom Burton will identify and design numerous different anti-inflammatory and anti-infective compounds. Sirona will be responsible for the chemistry, using its proprietary expertise in fluorination technology. Bloom Burton will be responsible for financing, clinical validation and commercialization of the compounds. At present, there are unmet market needs in the areas of rare or neglected inflammatory diseases and bacterial resistance. With the former, often overlooked and the latter, an emerging threat, the collaboration between Sirona and Bloom Burton will endeavor to help minimize the medical gap by maximizing on each of the companies' core competencies.

"We are extremely excited to be working alongside Bloom Burton, a national leader in healthcare-specialized investment banking" said Neil Belenkie, CEO of Sirona Biochem. "This joint venture will combine the best of our expertise to develop the compounds, expanding our product portfolio and delivering innovative solutions in therapeutic areas with unmet needs."

"We have always appreciated the strength of Sirona's chemistry platform and we are excited to explore opportunities in two important and unmet therapeutic indications," said Brian Bloom, President of Bloom Burton & Co. "In addition to capital raising, advisory, equity research and direct investments, Bloom Burton is excited to expand its activities to include company creation and incubation, which should create value for Sirona shareholders and our firm."

About Bloom Burton & Co.

Bloom Burton & Co. exists to accelerate monetization in healthcare. Bloom Burton has an experienced team of medical, scientific, pharmaceutical, legal and capital markets professionals who perform a deeper level of diligence, which combined with a creative and entrepreneurial culture, leads to the right monetizing events for companies and investors. Bloom Burton's many services include capital raising, mergers and acquisitions advisory, equity research, scientific and medical consulting, direct investing, company creation and incubation. For more information, please visit www.bloomburton.com.

About Sirona Biochem

Sirona Biochem is not a traditional biotech company. Sirona is a product-pipeline company with a proprietary technology platform developed at its laboratory facility in France. The company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds' efficacy and safety. Sirona Biochem's compounds are being developed for both pharmaceutical and cosmetic marketplaces and are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem's wholly-owned French laboratory is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information visit www.sironabiochem.com.


Antonia Issa
Communications Manager
Sirona Biochem Corp.
1.604.282.6065
[e-mail]


Read more at http://www.stockhouse.com/news/press-releases/2013/12/04/sir…

[Jon_Schnee]

Sirona Biochem Appoints Nigel Terrett to Board of Directors

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Nov. 28, 2013) - November 28, 2013 - Sirona Biochem Corp. (TSX VENTURE:SBM)(OTCQX:SRBCF) announced today the appointment of Nigel Terrett to its Board of Directors.

"We are thrilled that Nigel Terrett has agreed to join the team," said Neil Belenkie, Chief Executive Officer of Sirona Biochem. "Nigel's background in implementing successful strategic plans in life sciences, and his existing in-depth knowledge of Sirona through his work as our Strategic Advisor, will be an asset to us as we move forward in the growth and expansion of our business."

Sirona Biochem also announces that Chris Verrico will be stepping down from the company's Board of Directors. The company would like to extend its thanks and gratitude for his contribution.

About Nigel Terrett

Nigel Terrett has held many leadership roles in the life sciences sector some of which include his role of Chief Strategic Officer of LifeLabs Inc., Chairman of the Board at Excelleris Technologies, Senior Vice President of MDS Diagnostics Inc., and CIO within MDS Health Group. More recently, Nigel has provided strategic advisory services to the Biotech industry.

Read more at http://www.stockhouse.com/news/press-releases/2013/11/28/sir…

[Jon_Schnee]

Sirona Grants Stock Options

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Nov. 22, 2013) - Sirona Biochem Corp. (TSX VENTURE:SBM)(OTCQX:SRBCF)(FRANKFURT:ZSB) (the "Company") announces that it has granted, under its stock option plan, incentive stock options to directors, officers and consultants for the purchase of up to 2,150,000 common shares of the Company at a price of $0.15 per share for a period of five years.

About Sirona Biochem Corp.

Sirona Biochem is not a traditional biotech company. Sirona is a product-pipeline company with a proprietary technology platform developed at its laboratory facility in France. The company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds' efficacy and safety. Sirona Biochem's compounds are being developed for both pharmaceutical and cosmetic marketplaces and are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem's wholly-owned French laboratory is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information visit www.sironabiochem.com.

Read more at http://www.stockhouse.com/news/press-releases/2013/11/22/sir…

[Jon_Schnee]

Antwort auf Beitrag Nr.: 45.630.301 von Jon_Schnee am 15.10.13 14:29:12

wow. Company plannt in den nächsten 2.5 Jahre 30 neue Mitarbeiter im Labor von Frankreich einzustelen. Derzeit sind es 8 Mitarbeiter in Frankreich (Labor) und 8 in Kanada (Management, Finanzen, PR, etc...)

Dierve LOI Verträge sind abgeschlossen. Aber noch kein Fixer Vertrag.
Und Sirona drückt jetzt richtig auf Tempo mit der Entwicklung von neuen Compounds. Nicht ganz Risikoarm das ganze Unterfangen, doch bis jetzt Überzeugt mich das Management sehr.


Our near term goals include setting up future pipeline projects and growing our R&D infrastructure. In the next 30 months we plan to add 28 new employees and almost triple the size of TFChem, our laboratory in France. We are working now to fill our development pipeline with projects for our new chemistry teams. This growth plan is tied directly to our goal of significantly increasing the number of projects we are able to undertake concurrently. The greater the number of compounds we create, the greater the number of transactions and revenue generating partnerships that will drive our business growth and shareholder value.

[Jon_Schnee]

Sirona Biochem Corporation-CEO's Report on Progress

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Oct. 15, 2013) - Sirona Biochem Corp. (TSX VENTURE:SBM)(OTCQX:SRBCF)(FRANKFURT:ZSB) today provided a business update.

I'd like to take this opportunity to summarize Sirona Biochem's business and strategic growth over the past 12 months.

Financial

In October 2012, Sirona Biochem's share price hit a low of 4 cents and our market cap was $3 million CDN. We made the decision to raise money using a debt instrument to avoid a punitive equity financing. We raised $600,000 in debt which gave us the financial runway to grow the value of the company to a high of 14 cents per share and a market cap of more than $11 million on January 18th 2013.

February 22, 2013 we announced an equity financing target of $2.7 million and we closed the second tranche of this financing on April 30, 2013 having raised $1.8 million in equity.

September 11, 2013 we announced an equity financing target of $1 million and we oversubscribed the private placement, closing on September 19th having raised $1.17 million.

On October 11, 2013, Sirona's share price was 16.5 cents and our market cap was $17.83 million CDN, representing an increase in market capitalization of $14,644,394.00 CDN and a market capitalization increase of 560%.

As of October 11, 2013, Sirona Biochem's running 3 month average trading volume was in excess of 500,000 shares per day.

Strategy

The decision was made in November 2012 that we would de-risk our business model and simplify our operations.

Sirona' Biochem's business model:

Sirona Biochem's expertise is in creating new chemical compounds (pharmaceutical and cosmetic) that have distinct advantages over existing technologies. Each compound that we create will be licensed to an industry-leading company who will be responsible for developing, manufacturing and selling the compound. In return for the licenses, Sirona will receive licensing fees, milestone payments and ongoing royalty payments. The more compounds Sirona Biochem creates, the more revenue streams Sirona Biochem receives.

With this level of strategic focus, we diversify our risk across multiple projects, increase our portfolio size more quickly and continue to build our credibility and reputation as experts in the discovery of innovative therapeutics.

Operations

In November 2012 we restructured the company and downsized our corporate head office by one position. In our laboratory in France we assessed every project in development and made the decision to focus our resources on two projects (SGLT2 inhibitor and skin lightening) to ensure each would be completed and available for transaction within 6 months. All other projects were assigned a timeline for re-insertion into the development pipeline contingent upon the successful completion of our two prioritized projects.

Business Development

In the last 12 months we have attended / presented at the following meetings, conferences and events:

•In Cosmetics Asia (Thailand)
•In Cosmetics Europe (France)
•Bio Partnering North America (Vancouver)
•BioPharm America (Boston)
•BIO International Convention (Chicago)
•BIOTECanada CEO Summit (Chicago)
•BioInvestor Forum (San Francisco)
•Beijing, Tianjin, Guangzhou, Shanghai, China (2 trips - business development and investor relations)
•Paris, Rouen, France (5 trips - business development and management of TFChem)
•New York, USA (4 trips - investor relations and setting up strategic relationships)
•Tokyo, Yokohama, Japan (business development)
•California, USA (3 trips - business development and investor relations)
•Toronto, Canada (business development and investor relations)
•London, UK (Cosmetic Business Innovation Awards - Sirona Biochem's skin lightening compound was a finalist in the Innovation in Ingredients category, competing against Dow Chemical, Dove Spa, Mibelle Biochemistry and Seppic)

Our process for maximizing the potential value of our compounds is as follows: we connect with as many pharmaceutical, biotech, cosmetic and consumer health companies as possible that may have interest in our technology. Starting all of these discussions in parallel enables us to move the conversations forward within a predictable window of opportunity. These concurrent conversations create a competitive environment for our technology, maximizing its value within the marketplace.

Summary:

As a result of our international team's efforts, in the last 7 months Sirona Biochem has announced the following:

•Material Transfer Agreement with VitamFero, a member of Genopole, for testing of our biological preservation technology in combination with their live attenuated animal vaccines.

•Letter of Intent (LOI) with Biogalenys to develop preclinical data supporting multiple applications of Sirona Biochem's glycoprotein (cell preservation technology).

•Letter of Intent (LOI) with Cincinnati Children's Hospital Medical Center, the #3 ranked hospital among all honor roll hospitals in the USA. The goal of our collaboration is to combine our proprietary technologies to create a novel skin care technology which will be commercialized by a global leader in cosmetic or consumer packaged goods sales.

•Letter of Intent (LOI) with Wanbang Pharma, China's number one ranked anti-diabetic company. Wanbang Pharma will receive an exclusive license for sales of Sirona Biochem's SGLT2 Inhibitor in the People's Republic of China in return for licensing and clinical milestone fees and ongoing royalty payments. Wanbang Pharma will be responsible for funding all clinical studies and development of the SGLT2 Inhibitor and Sirona Biochem will receive all of the data generated by Wanbang Pharma with the goal of exponentially raising the value of Sirona Biochem's SGLT2 Inhibitor for licensing agreements throughout the rest of the world.

•Letter of Intent (LOI) with Obagi Medical Products for a global exclusive license of Sirona Biochem's skin lightening compound TFC-849. Obagi Medical Products will be responsible for all development, manufacturing and sales of the compound and in return Sirona Biochem will receive licensing and milestone fees and ongoing royalty payments.

•Letter of Intent (LOI) to create a joint venture with Bloom Burton and Co., Canada's largest and most active healthcare-specialized investment banking group. The goal of this joint venture is to conduct collaborative research to develop and commercialize new therapeutics in the areas of inflammation and infectious disease.

Moving forward we are strategically and operationally optimized to transition Sirona Biochem to its next phase of growth. Our short term focus is to formalize each of the LOIs that we have signed, confirming Sirona Biochem's first commercial transactions and predictable revenue streams. These formal agreements will mark the final transition from our being a research and development operation to a revenue generating business with globally recognized and respected brands as our partners.

Our near term goals include setting up future pipeline projects and growing our R&D infrastructure. In the next 30 months we plan to add 28 new employees and almost triple the size of TFChem, our laboratory in France. We are working now to fill our development pipeline with projects for our new chemistry teams. This growth plan is tied directly to our goal of significantly increasing the number of projects we are able to undertake concurrently. The greater the number of compounds we create, the greater the number of transactions and revenue generating partnerships that will drive our business growth and shareholder value.

Our overarching goal is for Sirona Biochem to become recognized as a global leader in the discovery of new products for leading cosmetic and pharmaceutical brands. Continued success creating commercially innovative and lucrative products for global brands will make Sirona Biochem a prized resource for the world's largest companies.

Best Regards,

Neil Belenkie, CEO

Sirona Biochem

About Sirona Biochem Corp.
Sirona Biochem is not a traditional biotech company. Sirona is a product-pipeline company with a proprietary technology platform developed at its laboratory facility in France. The company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds' efficacy and safety. Sirona Biochem's compounds are being developed for both pharmaceutical and cosmetic marketplaces and are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem's wholly-owned French laboratory is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information visit www.sironabiochem.com.

[Jon_Schnee]

Die Kanadier haben uns Entdeckt

Another board talks about Sirona Biochem

http://www.wallstreet-online.de/diskussion/1183167-51-60/sirona-biochem

Read more at http://www.stockhouse.com/companies/bullboard/v.sbm/sirona-b…...